IgA nephropathy
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
IgA nephropathy (IgAN) is the most frequent primary form of glomerulonephritis. The origin of IgAN is only partially understood and appears to involve the occurrence of IgA1, which is normally secreted by mucous membranes, in the circulation followed by its glomerular deposition and inflammatory changes. Clinically, IgAN mostly follows an inapparent course and the disease is often only first diagnosed by kidney biopsy when kidney function disorders are already manifested. Key prognostic indicators include the extent of proteinuria and the already manifested evidence of irreversible kidney damage. Treatment includes supportive measures. The effectiveness of high-dose systemic corticosteroid treatment in European patients is uncertain and controversial due to the adverse side effects. Nefecon (encapsulated budesonide) is the first specific drug licensed for treatment of high risk IgAN patients. A number of further approaches are currently in clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Urologie (Heidelberg, Germany) - 63(2024), 1 vom: 03. Jan., Seite 103-111 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
IgA-Nephropathie |
|---|
| Beteiligte Personen: |
Floege, Jürgen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
51333-22-3 |
|---|
| Anmerkungen: |
Date Completed 17.01.2024 Date Revised 17.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00120-023-02268-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36660886X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36660886X | ||
| 003 | DE-627 | ||
| 005 | 20240117232139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00120-023-02268-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1262.xml |
| 035 | |a (DE-627)NLM36660886X | ||
| 035 | |a (NLM)38170257 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Floege, Jürgen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IgA nephropathy |
| 246 | 3 | 3 | |a IgA-Nephropathie |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2024 | ||
| 500 | |a Date Revised 17.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a IgA nephropathy (IgAN) is the most frequent primary form of glomerulonephritis. The origin of IgAN is only partially understood and appears to involve the occurrence of IgA1, which is normally secreted by mucous membranes, in the circulation followed by its glomerular deposition and inflammatory changes. Clinically, IgAN mostly follows an inapparent course and the disease is often only first diagnosed by kidney biopsy when kidney function disorders are already manifested. Key prognostic indicators include the extent of proteinuria and the already manifested evidence of irreversible kidney damage. Treatment includes supportive measures. The effectiveness of high-dose systemic corticosteroid treatment in European patients is uncertain and controversial due to the adverse side effects. Nefecon (encapsulated budesonide) is the first specific drug licensed for treatment of high risk IgAN patients. A number of further approaches are currently in clinical trials | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Complement | |
| 650 | 4 | |a Glomerulonephritis | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 4 | |a Proteinuria | |
| 650 | 4 | |a Renin-angiotensin system | |
| 650 | 7 | |a Budesonide |2 NLM | |
| 650 | 7 | |a 51333-22-3 |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Urologie (Heidelberg, Germany) |d 2022 |g 63(2024), 1 vom: 03. Jan., Seite 103-111 |w (DE-627)NLM332860612 |x 2731-7072 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2024 |g number:1 |g day:03 |g month:01 |g pages:103-111 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00120-023-02268-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2024 |e 1 |b 03 |c 01 |h 103-111 | ||